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Abstract
This article reviews the rationale, sources and preparation of pig islets for 
xenotransplantation. Pancreatic islet cell transplantation is an attractive alternative 
and an effective treatment option for type 1 diabetes, however, donor pancreas 
shortages prevent islet transplantation from being a widespread solution as the 
supply cannot possibly equal the demand. Porcine islet xenotransplantation has 
the potential to address these shortages, and recent preclinical and clinical trials 
show promising scientific support. Pig islets provide a readily available source for 
islet transplantation, with the recent trials in non-human primates (NHPs) dem-
onstrating their potential to reverse diabetes. The risk of zoonosis can be reduced 
by designated pathogen-free breeding of the donor pigs, but porcine endogenous 
retroviruses (PERVs) which are integrated into the genome of all pigs, are especially 
difficult to eliminate. However, clinical trials have demonstrated an absence of 
PERV transmission with a significant reduction in the number of severe hypogly-
cemic episodes and up to 30% reduction in exogenous insulin doses. A number of 
methods are currently being tested to overcome the xenograft immune rejection. 
Some of these methods include the production of various transgenic pigs to better 
xenotransplantation efficiency and the encapsulation of islets to isolate them from 
the host immune system. Furthermore, ongoing research is also shedding light on 
factors such as the age and breed of the donor pig to determine the optimal islet 
quantity and function.
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Keypoints
• Preclinical studies show improvements in pig islet survival after transplantation.
• Clinical pig islet xenotransplantation studies prove no transmission of PERV.
• Pig islets can be successfully transplanted using encapsulation technology.
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1. Introduction to islet xeno-transplantation
Exogenous insulin is the most common treatment option for type I diabetes 
(insulin-dependent diabetes mellitus), a chronic metabolic disorder caused by the 
failure of the beta cells of pancreatic islets most often due to T-cell mediated auto 
immune reaction which result in hyperglycemia [1]. While the standard insulin 
therapy treats patients with diabetes, however, it does not cure the disease, nor 
does it prevent the development of the secondary complications leading to end 
stage organ failures along with its morbidity and mortality [2]. Technical advance-
ments in the production of exogenous insulin, better glucose monitoring system 
and optimal insulin therapy can reduce HbA1C but still has not addressed the 
issues of increasing hypoglycemic episodes in patients. Achievement of normogly-
cemia and exogenous insulin independence is the goal of diabetes treatment. The 
International Diabetes Federation (IDF) estimated the number of adults suffering 
from DM in 2017 to be 425 million: this number is expected to increase to 629 
million patients in 2040 [3]. Whole pancreas and pancreatic islet transplantation 
Figure 1. 
Trends in the number of organ donors (blue), organ transplants (green), and patients on the waiting list 
(Orange) in the US, 2003–2015. In 2003, there were 13,285 donors, 25,473 organ transplants, and 83,731 patients 
on the waiting list. By 2015, there were 15,068 donors, 30,975 organ transplants and 122,071 patients on the 
waiting list. Source: http://optn.transplant.hrsa.gov.
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are effective treatment options for diabetes by which insulin independence in 
T1D patients can be achieved [4]. Unfortunately, both whole organ and cellular 
transplantation face challenges due to a wide gap between the ever-increasing 
transplant waiting list and the supply of donor organs [5]. Data from the Organ 
Procurement and Transplant Network (OPTN) from 2003 to 2015, indicates a 
145% increase in the wait list for all organs, while donor availability increased by 
only 113% (Figure 1) [6]. Similarly, the total number of pancreases available is 
insufficient to match the need for pancreatic islet allo-transplantation [7–9].
Due to this shortage, xenotransplantation using porcine islets has emerged as a 
potential alternative source for beta cell replacement. Porcine islets have structural 
and physiological similarities to human islets. Porcine insulin (differs from human 
insulin by only one amino acid) is used to treat diabetes in clinical practice [10, 11]. 
Intact functional islets have been successfully isolated from the pig pancreas [12], 
and these islets have shown the ability to reverse diabetes when transplanted into 
NHPs [13]. This review article will present the evolution, current practices, chal-
lenges and perspectives for pig islet xenotransplantation.
2. History of islet xeno-transplantation
Xenotransplantation has been attempted for the past 300 years or so and blood 
xenotransfusion was tried as early as the seventeenth century by Jean Baptiste Denis 
[14]. This was later followed by corneal transplantations from pigs to humans and 
kidney transplantations in NHP [15, 16]. The first pancreatic xenotransplantation 
was performed by Watson et al., implanted three ovine fragments into the sub-
cutaneous plane of a diabetic patient. Though clinically significant blood glucose 
reduction was not demonstrated, the blood sugar level did decrease [17]. This 
pioneering work was followed by many experimental xenotransplantations, but 
results were mostly inconclusive [18–21]. Shumakov et al. reported 53 fetal porcine 
xenotransplants and 18 fetal bovine xenotranaplants in diabetic patients [22]. A 
century later, Groth et al. performed clinical xenotransplantation trial using fetal 
porcine islet cell-like clusters (ICCs) and provided preliminary data regarding 
the function and survival of grafts. After porcine islets were transplanted into 10 
insulin-dependent diabetic kidney-transplant patients, detectable levels of porcine 
C-peptide were identified in the urine for up to 400 days and in one case, renal graft 
biopsy showed insulin and glucagon positive cells after staining [23]. Several xeno-
transplantation studies have also been performed in NHPs [20], and have succeeded 
in reversing diabetes [24–27] and in reducing daily insulin dosage requirement [28]. 
Transplanted porcine islet grafts were also shown to survive and function in NHPs 
for longer than 6 months with immunosuppression [25, 27, 29]. The longest survival 
rate is now over 603 days according to Shin et al., [30]. Studies have also shown that 
microencapsulation of the transplanted islets and immune-isolation lead to better 
survival rate without the need for aggressive immunosuppressive therapy [26].
3. Pig islets as alternative source
The success of porcine insulin and its role in the treatment of T1D has been well 
established since its discovery in the 1920s [11, 12, 25]. The structural and physio-
logical similarities between human and pig organs, along with its unlimited supply, 
have made them an excellent translational research model [25]. Insulin extracted 
from pig islets has been used for the treatment of diabetes for decades [10, 11, 
20, 33]. Because porcine islets produce insulin patterns similar to those found in 
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humans, and because they are readily available [20], studies strongly suggest that 
islets obtained from pigs could be a promising substitute for human islets in the 
treatment of T1D. Recent studies on genetically engineered pigs suggest that these 
pigs are more suitable for xenotransplantation. For example, alpha 1,3-galactosyl-
transferase gene knockout (GTKO) pigs, have decreased the incidence of immune-
rejection and improved compatibility between the donor and recipient [31–36].
The major advantages for using pigs as an islet source for xenotransplantation 
are as follows:
1. Ethically acceptable source.
2. The pig pancreas has structural and physiological similarities to the human 
organ.
3. Unlimited availability.
4. Easy to breed and produce large litters.
5. Rapid growth into adult organs (6 months).
6. Significantly low cost of maintenance.
7. Elective and emergent availability of the organs.
8. Low risk of zoonosis.
9. Facilities available to breed pigs under ‘clean’ conditions.
10. Obviates ‘cultural barriers’ to human organ transplant (e.g. Japan); illegal 
organ trafficking; deleterious effects on organs in brain dead patients; living 
donor organ donation.
11. Advanced and safe immunosuppression protocols.
12. Cloning and genetic modification of cells to reduce immune destruction.
13. Islet encapsulation to combat immune challenge.
Modified from Ekser et al. [5]; Cooper et al. [37, 38]; Cheng et al. [20].
4. Selection of pig and sources of pig islets
Islet quantity and quality varies with the breed of pigs. Readily available market 
pigs have shown to yield lower when compared to the well-studied breeds of pigs like 
Landrace pigs, Chicago Medical School (CMS) miniature pigs and Chinese Wuzhishan 
(WZS) miniature pigs [23, 25, 27]. Two major factors which have been studied in 
relation to the source of pig islets for xenotransplantation are the breed and age of 
the donors. Some well-studied breeds are the Landrace pigs, Chicago Medical School 
(CMS) miniature pigs, and the Chinese Wuzhishan (WZS) miniature pigs. Market 
weight pigs are easily available, but studies have shown lower yields than for other 
breeds [39]. Landrace pigs have been shown to yield large sized (>250 μm) islets with a 
high islet volume density [39, 40]. Adult Chicago Medical School (CMS) miniature pigs 
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are bred under specific pathogen-free (SPF) conditions, and contain large-sized islets. 
The yield is greater than market or other miniature pigs (9589 ± 2838 IEQ/g), making 
CMS pigs one of the best sources for obtaining islets [39, 41–45]. Another miniature 
pig, the Chinese Wuzhishan (WZS) pig has also shown an islet yield greater than that 
of market pigs [39, 46]. Though no consensus has been arrived at the optimal breed for 
the preclinical/clinical studies, these breeds has been well documented to yield better 
islets than others. Higher expression of extracellular matrix (ECM) protein in islet 
capsules makes isolation easier and German Landrace pigs have higher ECM [24].
Additionally, age [43, 44, 47–49] and size of the donor pigs [36, 50–52] are major 
factors that affect islet isolation outcomes. Some studies have also suggested that 
gender may play a role in the final islet yield [39, 53, 54]. Pig islets can be obtained 
at four distinct life-stages: embryonic, fetal, neonatal and adult [55], and Table 1 
summarizes the significance, advantages, and disadvantages of pig islets from 
Islet source Significance Advantages Disadvantages
Embryonic In the dorsal pancreatic 
primordial, strands of 
insulin positive cells are seen 
as early as week 4 [43].
From week 13, cells 
exhibiting intense 
immunoreactivity for 
insulin are distributed 
throughout the pancreas 
[43, 57].
Embryonic pancreatic tissue 
exhibit predominantly 
insulin-positive beta cells 
without evidence of alpha 
cells [43, 58].
Use of embryonic primordial 
pancreas is better than 
pluripotent stem cells as they 
do not need steering toward 
pancreatic differentiation 
and have lower risk of 
teratoma [59].
Following transplantation, 
the exocrine tissue does 
not proliferate. Hence, 
there is decreased immune 
response and inflammatory 
complications.
Pancreatic primordia 
obtained on day 28 
successfully reversed diabetes 
in rhesus monkey when 
compared to that obtained 
on day 35, which underwent 
rejection [43, 60, 61].
Immaturity 
takes 8–12 weeks 
(~6 months) for 
maturation in vivo 
[43].
Poor insulin response 
post-transplantation 
due to immaturity [39, 
62–64].
Higher expression of 
alpha-1,3 galactose 
(Gal) when compared 
to adult—more 
susceptible for 
humoral rejection.
Low yield—only 
a small number of 
islets can be isolated, 
requiring large 
number of pigs which 
limits large scale 
clinical application, 
with ethical issues.
Fetal Porcine islets are isolated 
from fetuses of 60–69 days 
gestational age [36, 65].
Islets lack a definite 
shape and capsule and 
are organized in clusters 
(ICCs) [36].
These cellular clusters 
are composed of <40% 
endocrine cells (6–8% beta 
cells) with the majority 
being the cytokeratin-
positive epithelial cells [65].
Their ability to proliferate 
makes them a potential 
source of islet cells [27, 36, 
66–68].
Isolation process is very 
simple, involving digestion of 
the pancreatic tissue to free 
the islet clusters [65, 69].
No gradient purification 
necessary.
Easily scalable to provide 
clinical product.
Isolation not dependent on 
the enzyme collagenase, 
(activity is variable between 
enzyme lots).
The use of alpha 
1,3-galactosyltransferase 
GTKO strains has 
demonstrated better 
transplant outcomes than 
wild-type strains [43, 70].
Cellular culture is 
required for 5–9 days 
to form cellular 
aggregates.
Maturation of islets is 
delayed
Demands higher 
number of pigs to 
provide sufficient 
islets due to lower 
yield [27, 36, 71].
Because of their 
clustered appearance, 
it is difficult to 
separate islets from 
the surrounding 
exocrine and other 
non-islet cells [36].
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different donor life-stages. Adult pigs have been preferred for their higher yield of 
mature islet cells that have the potential to secrete insulin soon after transplanta-
tion. However, the higher costs, fragility of the islets and the difficulty in isolation 
are the disadvantages. Neonatal and fetal islets are easy and inexpensive to isolate 
but the main disadvantage is the significant delay in functioning after transplanta-
tion due to their immaturity and their high expression of Galactose-α-1,3-galactose 
(αGal), the major antigenic target for primate anti-pig antibodies [56].
Islet source Significance Advantages Disadvantages
Neonatal The neonatal period is up 
to 30 days after birth. NPIs 
are usually obtained from 
the pancreas within the first 
week of life [43].
NPIs comprise ~35% of 
endocrine cells and ~57% 
of epithelial cells—islet 
precursor cells [39, 72, 73].
Correct hyperglycaemia 
in diabetic animal models 
as the precursor cells also 
differentiate and proliferate 
into beta cells [27, 36, 39, 
74, 75].
The cellular aggregates 
are composed of <40% 
endocrine cells (20–25% 
beta cells) with majority 
being cytokeratin-positive 
epithelial cells [65].
About 10–13 days after 
birth, the ICCs begin to 
resemble adult islets [43, 57].
Isolation process is very 
simple—the process involves 
digesting pancreatic tissue 
simply to free islet clusters 
[65, 72].
No gradient purification.
Easily scalable to provide 
clinical product.
Isolation not dependent on the 
enzyme collagenase (activity 
is variable between lots).
Isolation process is less 
expensive than for adult islets.
Maintenance of neonates is 
easy and inexpensive as they 
are maintained only for few 
days postpartum.
Exhibit strong resistance to 
inflammatory and hypoxia-
induced injury.
Lower T-cell reactivity than 
adult pigs [39, 76, 77].
Potential alternative to adult 
pig islets as xenografts.
Maturation is delayed 
when compared to 
adult islets but is 
faster than for fetal 
ICCs.
Cellular culture is 
required for 5–9 days 
to form cellular 
aggregates.
Lower yield—limits 
clinical usage. Only 
50,000 aggregates can 
be obtained from a 
single pancreas when 
compared to adult.
Adult Adult pig islets (APIs) are 
the major source of islet cells 
for xenotransplantation [39, 
78–80].
APIs are well differentiated 
with distinct and intact 
capsule and vasculature 
with very few insulin 
positive cells outside these 
islets [43, 57].
Antigenicity is from 
N-linked sugars and not 
from Gal Ag [39, 43, 81–83].
The expression of Gal Ag 
decreases and becomes 
negligible as the pig reaches 
adulthood [43, 81–86].
>2 yrs. is the optimal age 
[36, 39, 50, 54, 87].
Adult islets are 
predominantly islet 
endocrine cells.
Morphologically distinct—
can be extracted and purified 
as a single unit [36].
Mature cells—response to 
hyperglycemia is immediate 
following transplantation 
without latency [36, 39, 43, 
87–90].
Insulin independence in 
diabetic NHPs is achieved 
when ≥10,000 IEQs are 
transplanted. (islets pooled 
from 2 to 4 adult pigs) 
[39, 80].
Do not require culturing of 
the isolated islets [65].
Islet yield is greater than for 
fetal and neonatal pigs [43, 
78, 91].
Isolation is technically 
challenging, complex 
and expensive [36, 43, 
65, 79, 92–94].
More fragile 
islets [65].
Difficult to 
scale-up [65].
Highly dependent on 
the enzyme lot and 
activity [65].
Requires gradient 
purification [65].
Very high cost of 
maintenance and 
breeding in a clean 
isolated environment 
[36, 43, 47].
Bigger size of the 
animal is associated 
with surgical 
complications during 
organ procurement 
[36, 50].
Table 1. 
Different sources of pig islets; significance, advantages, and disadvantages.
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5. Pig islet isolation
Adult pig islet preparation is very similar to human islet isolation methods [55] 
but the digestion process is a lot more gentler as the porcine islets are extremely 
fragile. Methods of islet preparation may vary depending on the life-stage of the 
donor pancreas. Fetal pig ICCs and neonatal pig islets (NPIs) are immature cells 
and can be easily isolated by enzymatic digestion [55] but must subsequently be 
cultured prior to transplantation to promote re-aggregation of islet clusters and to 
help eliminate exocrine cells [55]. The digestion procedure for the adult pig pan-
creas is significantly different over the fetal or neonatal pancreas. Many factors, 
such as the type of donor pigs, blood exsanguination, warm ischemia time, cold 
ischemia time, enzyme lot and activity, perfusate, and the isolation-purification 
process significantly affect the final islet yield, function and viability [39, 54, 55, 
79, 95–97].
5.1 In vitro and in vivo assessment of pig islet function
In vitro studies investigating the insulin response of islets from donor pigs of 
different ages have shown that the insulin response from adult pig islets is more 
pronounced and sustained, and that they have a higher stimulation index over young 
pigs [36]. Islets from different age of donor pigs have also been compared in vivo. 
Two groups of diabetic nude mice populations were implanted with either young 
and young adult porcine islets or adult islets. One out of 11 recipients of young and 
young-adult islets achieved normoglycemia, whereas 32 out of 39 transplanted with 
adult islets became normal, the blood glucose reaching normal range within 4 weeks 
post-transplantation. Graft function was confirmed as the cause for normoglycemia, 
as all 32 mice reverted back to hyperglycemia after islet graft removal [36]. Many 
studies using NHP models have demonstrated the benefits of the pig islets as xeno-
transplants, with a potential cure for diabetes [25, 39, 98–101]. These studies have 
shown diabetes reversal with prolonged graft survival in diabetic NHPs.
5.2 Hurdles for xenotransplantation
Prevention of the transmission of porcine endogenous retrovirus (PERV) and 
immunological reactions have been the major hurdles for xenotransplantation in 
preclinical and clinical trials. Though the risks of zoonosis have been downplayed 
significantly with the introduction of genetically modified pigs, immunological 
responses like instant blood mediated inflammatory response (IBMR) dictate the 
success of the graft survival. One of the most important risk to overcome during 
xenotransplantation is the prevention of zoonosis [102]. Porcine endogenous ret-
roviruses (PERVs) are of special concern as they are found integrated with porcine 
genomes and are difficult to eliminate [102]. The degree of risk of PERV being 
able to infect the human host is unknown, but evidence has shown that PERV can 
infect human cells when co-cultured with human EK-293 cells [55, 103]. Cross-
species transmission has also been documented in pig to SCID mice xenotrans-
plantation [55, 104]. However, no evidence of transmission has been documented 
in T1D patients who received porcine islet transplants, even after prolonged 
follow-up [55, 105].
Apart from PERV, other pathogenic organisms including the herpes virus, lym-
photropic herpes virus, and cytomegalovirus can also be transmitted. [55]. Methods 
of combatting these pathogens include careful assessment and screening protocols, 
designated pathogen-free (DPF) breeding and housing of PERV gene knockout 
pigs, all of which can help minimize the risk of zoonotic infections [29]. DPF herds 
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must be free from a comprehensive and list of specified microorganisms [29, 106] 
and meticulous documentation and standard operating procedures (SOPs) must be 
implemented to maintain this status [29] including feed restrictions [29].
5.3 Immunological response
Pig islet cells express different surface proteins that play a major role in the 
immunological rejection seen following transplantation [102, 107]. Immunological 
responses are much more complex than seen in allo-transplantation [102]. Immune 
mediated inflammatory response have been brought down by significantly by 
genetic modifications as summarized in Table 2. Hyper acute rejection (HAR), 
Instant blood mediated inflammatory response (IBMIR), and cellular rejection are 
the types of responses seen in graft rejection of which IBMIR is the most crucial. 
Portal vein site provides good revascularization and drainage for islet transplanta-
tion but due to the severe complications like bleeding, thrombosis, and hepatic 
steatosis, it is no longer an optimal site [108]. Immunological issues observed during 
xenotransplantation are similar to those seen in allo-transplantation but are much 
more complex [102]. Pig islets express different types of surface proteins, and these 
play a critical role in the immunologic rejection seen following transplantation 
[107]. Multiple genetic modifications in pigs have been proposed to significantly 
reduce immune mediated inflammatory response, and these are summarized in 
Table 2.
There are four known major routes for islet cell loss following transplantation 
and these are summarized in the following sections.
5.3.1 Hyper acute rejection (HAR)
HAR occurs due to the presence of pre-existing host antibodies to surface 
proteins on the porcine islets. These surface proteins can be broadly categorized into 
Gal and non-Gal proteins [34, 38, 110]. The Gal epitope is absent in humans, apes 
and old-world monkeys but many bacteria, NHP and new world monkeys express 
Immune related islet injury Genetic modifications References
Ischemia/reperfusion injury and 
inflammatory cytokine related injury
Expression of human heme oxygenase-1
GTKO pigs/hCRP pigs
[55, 109]
[110–112]
Humoral rejection GTKO
CD46 (membrane cofactor protein)
CD59 (MAC-inhibitory protein)
CD55 (decay accelerating factor)
[55, 
113–115]
[116]
[117]
IBMIR and coagulation dysfunction TF knockout and overexpression of human 
antithrombotic genes (CD39/thrombomodulin)
ENTPD1 expression
Mesenchymal stem cell (MSC) 
co-transplantation
[55, 118]
[39, 119]
[110, 120]
Cellular rejection CTLA4Ig gene expression
GTKO pigs/hCRP pigs
MSC co-transplantation—downregulate T-cell 
response (immunomodulator)
[55, 121]
[110–112, 
122]
[39, 120, 
123]
[117]
Table 2. 
Genetic modifications in pigs to overcome immunological rejection.
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the Gal epitope abundantly. In pigs, the expression of Gal antigens decreases as they 
grow into adults [84, 102, 110, 124, 125].
As the human body is continuously exposed to micro-organisms (including 
bacteria), it develops immunity to the Gal antigen and has pre-formed, circulating 
anti-Gal antibodies [107, 126], which make up around 1% of the circulating anti-
bodies [102, 124]. Once the pigs islets are transplanted, these pre-formed anti-
bodies kill the islet cells rapidly by complement mediated destruction [107, 124] 
resulting in substantial islet loss [102, 107, 127].
Antibodies are also produced for other surface epitopes (non-Gal Ag) such as 
N-glycolylneuraminic acid (NeuGc) also known as Hanganutzu-Deicher and beta 
1,4 N-acetylgalactosaminyltransferase (B4GALNT2) [107, 128–130] which are also 
involved in complement mediated destruction of xenografts [107].
There are two known strategies for prevention of HAR. Knockout of genes 
responsible for adding the Gal epitope and other epitopes such as Neu5Gc to the 
cell surface can prevent their expression [34, 102]. Secondly, expression of comple-
ment regulatory proteins such as hCD46, hCD55 and hCD59 can be induced on the 
surface of the islet cells [102, 131]. Double knockout pigs (deficient in alpha-gal 
(GTKO) and Neu5Gc) have been produced, which has significantly reduced the 
incidence of humoral rejection [102, 132]. The Gal antigen is highly expressed 
in fetal and neonatal pig pancreas, but its expression decreases as the pigs reach 
adulthood. The use of GTKO pigs is more validated when using fetal or neonatal 
pancreas [85, 116], but is not as essential when using adult pigs [116]. However, 
increasing titres of anti-Gal IgG antibody have been noted when immunosuppres-
sion is stopped after adult pig islet transplant [30, 116], so GTKO pigs may prove 
beneficial even for islets isolated from adult pigs.
5.3.2 Instant blood mediated inflammatory reaction (IBMIR)
Following the intra-portal infusion of the pig islets, the elevated expression of 
tissue factor by the islets initiates IBMIR [39]. The IBMIR contributes to significant 
islet loss in the early post-transplant phase through a series of events involving 
simultaneous complement activation (alternative pathway) [81, 86], activation 
of intrinsic and extrinsic coagulation pathways, and platelet activation (platelet 
aggregates around the islets P6) followed by neutrophil and monocyte infiltration 
[110, 116, 133, 134]. IBMIR can result in 60–80% of islet loss in the immediate 
post-transplant period [39, 55, 110, 118, 135], but studies in NHPs have shown that 
if a sufficient number of islet cells survive, they can establish normoglycemia for 
several months [110]. Genetically modified pigs have been produced [110, 136] 
to combat IBMIR by decreasing the load of xenoantigens but it failed to provide 
long-term protection against host response [137]. Experimental studies involving 
control of complement activation by cobra venom factor, and platelet aggregation 
and coagulation by anti-platelet agents and low molecular weight heparins are not 
proven clinically safe, [138, 139]. Peritoneal cavity and omentum offer alternative 
sites for transplantation of encapsulated islets [140].
5.3.3 Cellular rejection
Cellular rejection, a CD4+ T-cell-dependent process [55, 141–143], plays a 
major role in islet destruction [39, 118, 144, 145]. Acute cellular rejection occurs 
within 24 h to 20 days post-transplant, and is characterized by a massive infiltra-
tion of macrophages and T-cells (CD4+ and CD8+cells). Two signaling pathways 
required for the full activation of T cells are the T cell receptor signaling, and the 
co-stimulatory signaling [55, 146]. Since T cell activation requires double signaling 
Xenotransplantation - Comprehensive Study
10
involving TCRs and co-stimulatory molecules [39], blockade of co-stimulatory 
cell surface molecules such as CD870/86- CD28 and/or CD40L (CD154)- CD40 
have significantly improved graft survival, even without immunosuppression [39, 
147–149]. The addition of targeted immunosuppression to multi-molecular block-
ade may further increase effectiveness, and provide an even more promising option 
to prevent cellular destruction of the transplanted islets [39].
5.3.4 Islet cell revascularization
Islet revascularization is critical for the survival of transplanted pig islets. Islet 
grafts are cut off from their native vascular supply and after transplantation, are 
solely dependent on diffusion for nutrient supply, until functional revascularization 
is established with the host vasculature. This process takes place within 10–14 days 
post-transplantation [41, 49, 141].
6. Islet encapsulation approaches
Islet encapsulation provides the means for islet cell survival in the absence of 
immunosuppressive drugs. The principle of encapsulation is that transplanted 
cells are contained within an artificial compartment separated from the immune 
system by a semipermeable membrane. The capsule should protect the cells from 
potential damage caused by antibodies, complement proteins, and immune cells. 
Therefore, the capsule is often referred to as an “immunoisolation device.” As well 
as the protective mechanism provided by the capsules, islet cells within the capsules 
can also release insulin to control blood glucose levels, since this membrane enables 
small molecules to diffuse in (glucose, oxygen, and nutrients) and out (metabolic 
wastes) [39, 150–152]. Thus, the encapsulation system is also regarded as a “bio-
artificial pancreas.” The immunoisolation device or bioartificial pancreas can be 
commonly separated into two categories, intravascular and extravascular devices. 
The latter can further be divided into macroencapsulation and microencapsulation 
devices. Intravascular and extravascular classifications are based on whether or not 
it is connected directly to the blood circulation.
The macroencapsulation and microencapsulation classifications depend on 
whether it contains one or more islets in the device [153, 154]. Alginate is the most 
commonly used capsule material for microencapsulation, but other materials such 
polyethylene glycol have also been tested [153].
Although the capsule is selectively permeable, islets can be damaged due to 
hypoxia or inadequate nutrients, and slow glucose and insulin diffusion can delay 
insulin response to changing glucose levels [155]. Despite the protection offered 
from direct immune attack, islets can still be damaged by immune responses. 
Inflammatory cytokines, produced against the capsules can enter the capsule and 
damage islets. The encapsulated islets themselves may release such cytokines and 
cause self-damage [156]. Approaches investigated to overcome these problems 
include testing different sites of implantation, creating biocompatible capsules, 
and optimizing the capsule size. The use of genetically engineered pig islets within 
capsules to promote graft survival and function have also been studied [156]. 
Several clinical trials of encapsulated pig islets to improve long-term survival 
outcomes of xenografts are currently being conducted around the world [117, 157]. 
A phase I/IIa clinical study in Moscow has tested the clinical applicability of a com-
mercially available encapsulated pig islet product called Diabecell [39, 158, 159]. 
Additional phase I/IIa clinical trials are ongoing in New Zealand and Argentina. 
These trials have demonstrated an absence of PERV transmission, a significant 
11
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reduction in the number of severe hypoglycaemic episodes and up to 30% reduc-
tion in exogenous insulin doses [29, 160]. A 10 year follow up of another study 
involving xenotransplantation of encapsulated porcine islets into the peritoneum 
of a T1D patient has shown long-term islet survival and function, with no evidence 
of PERV infection [39, 150].
7. Regulatory aspects
Any new therapeutic substance or procedure, safety and efficacy of the drug 
substance have been inveterate before starting government approved clini-
cal trials. In line with guidance in consensus statements from the International 
Xenotransplantation Association and the WHO on xenotransplantation, geographi-
cal location will impact choice of the microbiological mitigation strategy. Risk 
management at the source would include the definition of pathogens circulating 
in the countries of origin [161], establishment of reliable detection, and screening 
methods and assessment of risk from animal feed. Given the source animals to 
be utilized will be from specific pathogen-free/designated pathogen-free or high 
hygienic herds from a single location, the pathogen risk compared with standard 
slaughter herd animals is significantly reduced. Further testing during the manu-
facturing process, that is, islet isolation and encapsulation will provide tissue 
specific data that should further confirm safety of the final product. Moreover, 
alginate encapsulation allows keeping the islets in culture for longer periods thus 
giving enough time to perform viral screening on islet products before transplanta-
tion. Other release quality controls related to islet morphology, viability, purity, 
quantity, and potency should also be established in order to guarantee that only 
well characterized and functional islet preparations are used in patients. The use of 
genetically modified donor pigs to reduce islet cells immunogenicity and improve 
their secretory function stipulates that these genetic modifications should be well 
characterized. Integration of transgene expression cassettes should be in well-
defined genomic locations, preferably in the form of a single-targeted integration 
that would ensure stable expression of the transgene across herds without affecting 
other cell functions or rendering them tumorigenic. In this context, it should be 
noted that encapsulation limits the risk of tumor cells spreading since it confines 
the cells and eliminates the need for immunosuppression meaning that in case the 
integrity of the encapsulation device would be compromised, xenogeneic pig cells 
would most probably be rejected by the host immune system. The use of nonhuman 
primates in research is subjected to very strict ethical and regulatory considerations 
but the pig-to-primate model is still considered as a gold standard for pig islet 
xenotransplantation, so that safety and efficacy data obtained using this model are 
required before initiating clinical studies [162].
8. Conclusion
Porcine islets represent an excellent alternative source to replace human islets 
in diabetic patients. Pig islets can be obtained from different life-stages (embryos 
to adults) and has several other advantages making it an indispensable resource for 
xenotransplantation. Active research have resulted in standardization of protocols, 
thereby bettering isolation outcomes. In addition, incorporation of multiple strate-
gies such as generating transgenic pigs together with developing cellular and molec-
ular therapies to sustain long-term xenograft survival have brought porcine islets 
closer to clinical applications. Despite the risk of zoonosis and other factors which 
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contribute to islet loss post-transplantation, tremendous progress has been made 
within the field such as developing encapsulated islets to combat host immunity and 
utilizing host stem cells to aide islet revascularization. Pig islet xenotransplantation 
currently acts as a bridge between allo-transplantation and stem-cell therapies. 
With all the tremendous progress made within the field, ongoing research focuses 
on a better understanding of various factors such as donor characteristics, isolation 
procedures, microbiological safety, and immunological tolerance to improve pig 
islet yield, function and transplantation outcomes. Furthering this understanding 
will require multiple clinical trials directed toward establishing porcine islets as a 
safe, effective and robust alternative for treating patients with T1D.
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